A Phase I/II Study of Ixazomib plus Cyclophosphamide and Dexamethasone for Newly Diagnosed Light Chain Amyloidosis


Full Title

TX16039: Phase 1/2 Study of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Patients with Newly Diagnosed Immunoglobulin Light Chain AL Amyloidoisis


Amyloidosis is a disorder in which abnormal proteins build up in tissues and organs. Clumps of the abnormal proteins are called amyloid deposits. Amyloidosis may be treated with chemotherapy, but the disease often returns. The purpose of this study is to evaluate the safety and effectiveness of giving the drug ixazomib in combination with cyclophosphamide and dexamethasone in patients newly diagnosed with light chain amyloidosis.

Ixazomib is a “proteasome inhibitor.” These drugs inhibit many proteins (known as proteasomes) that cancer cells need to survive and multiply. Ixazomib is approved for treating multiple myeloma; its use in this study is considered investigational. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have light chain amyloidosis that has not yet been treated.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Heather Landau at 212-639-8808.